CIK 0001855175 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Contineum Therapeutics, Inc.
Sign in to watch- Ticker
- CTNM
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 271467257
- Phone
- (858) 333-5280
- Business address
- 3565 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO, CA, 92121
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $41,142
- in 1 filing, $41K under 10b5-1 plans
Net −$41,142. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-02-11 | Stengone Carmine N. CEO and President | Option exercise 10b5-1 | +400 | $1.26 | $504 | 15,354 |
| 2026-02-11 | Stengone Carmine N. CEO and President | Sale 10b5-1 | −400 | $16.00 | $6K | 14,954 |
| 2026-02-11 | Stengone Carmine N. CEO and President | Option exercise · Stock Option (right to buy) 10b5-1 | −400 | 128,017 | ||
| 2026-02-11 | Lorrain Daniel S. Chief Scientific Officer | Option exercise 10b5-1 | +400 | $1.01 | $404 | 156,452 |
| 2026-02-11 | Lorrain Daniel S. Chief Scientific Officer | Sale 10b5-1 | −400 | $16.00 | $6K | 156,052 |
| 2026-02-11 | Lorrain Daniel S. Chief Scientific Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −400 | 75,530 | ||
| 2026-02-03 | Lorrain Daniel S. Chief Scientific Officer | Sale 10b5-1 | −3,000 | $14.82 | $44K | 157,222 |
| 2026-02-03 | Lorrain Daniel S. Chief Scientific Officer | Sale 10b5-1 | −1,170 | $15.25 | $18K | 156,052 |
| 2026-01-30 | Healy John Stephen General Counsel and Corp Sec | Grant or award · Stock Option (right to buy) | +206,411 | 206,411 | ||
| 2026-01-30 | Slover Peter T Chief Financial Officer | Grant or award · Stock Option (right to buy) | +192,000 | 192,000 | ||
| 2026-01-30 | Stengone Carmine N. CEO and President | Grant or award · Stock Option (right to buy) | +445,000 | 445,000 | ||
| 2026-01-30 | Lorrain Daniel S. Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +160,000 | 160,000 | ||
| 2026-01-30 | Lorrain Daniel S. Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +6,500 | 6,500 | ||
| 2026-01-30 | Watkins Tim CMO & Head of Development | Grant or award · Stock Option (right to buy) 10b5-1 | +160,000 | 160,000 | ||
| 2026-01-28 | Watkins Tim CMO & Head of Development | Option exercise 10b5-1 | +3,611 | $4.50 | $16K | 3,611 |
| 2026-01-28 | Watkins Tim CMO & Head of Development | Sale 10b5-1 | −2,800 | $14.09 | $39K | 811 |
| 2026-01-28 | Watkins Tim CMO & Head of Development | Sale 10b5-1 | −811 | $14.48 | $12K | 0 |
| 2026-01-28 | Watkins Tim CMO & Head of Development | Option exercise · Stock Option (right to buy) 10b5-1 | −3,611 | 252,778 | ||
| 2026-01-05 | Lorrain Daniel S. Chief Scientific Officer | Sale 10b5-1 | −3,670 | $10.35 | $38K | 160,722 |
| 2026-01-05 | Lorrain Daniel S. Chief Scientific Officer | Sale 10b5-1 | −500 | $11.13 | $6K | 160,222 |
Page 4 of 7 · 139 trades